Advasure

Withdrawn

This medicine's authorisation has been withdrawn

adjuvanted vaccine against classical swine fever

Overview

The marketing authorisation for Advasure has been withdrawn at the request of the marketing authorisation holder.

Advasure : EPAR - Summary for the public

Product information

Advasure : EPAR - Product Information

Advasure : EPAR - All Authorised presentations

Product details

• Name of medicine:
  Advasure
• Active substance:
  E2 glycoprotein of classical swine fever virus
• International non-proprietary name (INN) or common name:
  adjuvanted vaccine against classical swine fever
• Species:
  Pigs
• Anatomical therapeutic chemical veterinary (ATCvet) code:
  QI09AA06

Pharmacotherapeutic group

Immunologicals for suidae

Therapeutic indication

Active immunisation of pigs, over the age of 2 weeks, against Classical Swine Fever (CSF), to prevent
mortality, reduce clinical signs of the disease and the excretion of field virus.
The onset of protection is 2 weeks.
The duration of protection is 6 months.

Authorisation details

• EMA product number:
  EMEA/V/C/000053
• Marketing authorisation holder:
  Pfizer Limited

  Ramsgate Road; Sandwich; Kent; CT13 9NJ; United Kingdom

• Marketing authorisation issued:
  02/02/2001
• Revision:
  5

Assessment history

Changes since initial authorisation of medicine

Advasure : EPAR - Procedural steps taken and scientific information after authorisation

Initial marketing authorisation documents

Advasure : EPAR - Scientific Discussion

Advasure : EPAR - Procedural steps taken before authorisation